466 results on '"Mayer, Erica L."'
Search Results
102. Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic
103. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
104. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel
105. Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer
106. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
107. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
108. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
109. A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131
110. Anti-Angiogenic Strategies in Breast Cancer: An Update
111. Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy.
112. Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship.
113. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
114. The effects of a clinic‐based weight loss program on health‐related quality of life and weight maintenance in cancer survivors: A randomized controlled trial.
115. Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology.
116. Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy
117. Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer
118. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
119. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)
120. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
121. Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)
122. Aromatase Inhibitors for Breast Cancer Treatment and Prevention
123. Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer
124. TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker.
125. Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.
126. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL
127. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: RadiologyScientific Expert Panel
128. Effect of the LIVESTRONG® at the YMCA exercise program on physical activity, fitness, quality of life and fatigue in cancer survivors
129. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial).
130. Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record
131. Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.
132. Randomized trial of a clinic-based weight loss intervention in cancer survivors
133. Postmenopausal breast cancer: a best endocrine strategy?
134. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor–Positive Breast Cancer
135. Genomic profiling of ER+breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
136. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
137. Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis
138. Implementation to optimization: A tailored, data-driven approach to improve provider efficiency in using the electronic medical record.
139. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
140. Tamoxifen Directly Inhibits Platelet Activation, Angiogenic Potential and Platelet-Mediated Metastasis
141. Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors
142. Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
143. Council Clinical Perspective: Cardiovascular Health of Patients with Cancer and Cancer Survivors: A Roadmap to the Next Level
144. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
145. Immediate breast reconstruction following mastectomy in pregnant women with breast cancer
146. Virtual consults: A paradigm shift for second opinions in oncology care.
147. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment
148. A randomized trial of a clinic-based weight loss intervention in cancer survivors.
149. evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
150. Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.